scholarly journals Comparison of Outcomes Between Mometasone Furoate Intranasal Spray and Oral Montelukast in Patients with Allergic Rhinitis

2020 ◽  
Vol 18 (2) ◽  
pp. 268-270
Author(s):  
Sushma Bhattachan ◽  
Yogesh Neupane ◽  
Bibhu Pradhan ◽  
Naramaya Thapa
Keyword(s):  
Allergic Rhinitis ◽  
Symptom Score ◽  
Nasal Symptom ◽  
Mometasone Furoate ◽  
Total Ige ◽  
Total Nasal Symptom Score ◽  
Medication Score ◽  
The Mean ◽  
Serum Total Ige ◽  
Intranasal Spray

Background: Allergic rhinitis is a common ailment with rising trend and worldwide prevalence of some 400 million. Methods: This prospective randomized crosssectional study was done at the Department of Otorhinolaryngology and Head and Neck Surgery, Tribhuvan University, Teaching Hospital, Kathmandu, Nepal from June 2016 to August 2017. They were randomly assigned to two groups by lottery method. Group A received mometasone furoate intranasal spray and Group B received oral montelukast for a total duration of one month. Prior to starting medication and one month after medications, total nasal symptom score was documented. Statistical analysis was done using SPSS version 18.Results: Total of 126 patients between 16 to 52 years were enrolled in the study. The mean duration of symptoms was 3.93 years. The mean value of serum total IgE was 833.49 IU/ml. The mean pre and post medication score for mometasone furoate intranasal spray group was 16.32 and 5.44 respectively, which was significant. Similarly, the mean pre and post medication score for oral montelukast group was 15.24 and 7.87 respectively which was also found to be significant. Comparing the means of scores for both the groups, mometasone furoate was found to be more effective than oral montelukast.Conclusions: Both mometasone furoate intranasal spray and oral montelukast were effective in the treatment of patient with allergic rhinitis. Oral montelukast can therefore be used as a first line treatment for patients with allergic rhinitis. Keywords: Allergic rhinitis; mometasone furoate intranasal spray; montelukast; serum total IgE; total nasal symptom score.

scholarly journals Efektivitas salin hipertonik terhadap waktu transpor mukosiliar dan skor gejala hidung penderita rinitis alergi

2018 ◽  
Vol 47 (2) ◽  
pp. 123
Author(s):  
Woro Safitri ◽  
Dwi Reno Pawarti ◽  
Titiek Hidayati Ahadiah
Keyword(s):  
Clinical Trial ◽  
Allergic Rhinitis ◽  
Symptom Score ◽  
Saline Group ◽  
Nasal Symptom ◽  
Control Group ◽  
Mucociliary Transport ◽  
Transport Time ◽  
Total Nasal Symptom Score ◽  
The Mean

Latar belakang: Rinitis alergi (RA) adalah suatu penyakit inflamasi mukosa hidung yang diperantara oleh imunoglobulin E (IgE), setelah mukosa hidung terpapar alergen. Tujuan: Mengidentifikasi efektivitas cuci hidung salin hipertonik terhadap waktu transpor mukosiliar dan skor gejala hidung total (SGHT) pada penderita RA. Metode: Penelitian dilaksanakan pada bulan Juli hingga Desember 2016 di Poli Telinga Hidung Tenggorok – Bedah Kepala Leher Rumah Sakit Dr. Soetomo Surabaya. Uji klinis acak terkontrol pada 2 kelompok dengan desain control group in clinical trial. Pengambilan sampel dilakukan secara consecutive sampling. Uji korelasi yang digunakan adalah uji t berpasangan dan uji Wilcoxon. Hasil: Didapatkan sampel 42 penderita, yaitu 21 penderita pada kelompok loratadin, serta 21 penderita pada kelompok loratadin dan cuci hidung salin hipertonik. Didapatkan rerata penurunan transpor mukosiliar kelompok loratadin dan cuci hidung salin hipertonik lebih bermakna daripada kelompok loratadin (p=0,001). Penurunan transpor mukosiliar kelompok loratadin didapatkan rerata -2,30 (SD=2,77), kelompok loratadin dan cuci hidung salin hipertonik didapatkan rerata -6,27 (SD=3,91). Penurunan SGHT kelompok loratadin didapatkan rerata -2,48 (SD=1,72), sedangkan kelompok loratadin dan cuci hidung salin hipertonik didapatkan rerata -4,3 (SD=1,20). Kesimpulan: Penambahan cuci hidung salin hipertonik pada terapi loratadin lebih efektif dibandingkan terapi tunggal loratadin dalam menurunkan transpor mukosiliar dan SGHT pada penderita RA. Kata kunci: Loratadin, cuci hidung salin hipertonik, transpor mukosiliar, skor gejala hidung total, rinitis alergi ABSTRACT Background: Allergic rhinitis (AR) is a nasal mucous membrane inflamatory which mediated by Imunoglobulin E (IgE) after allergen exposure in nasal mucosa. Purpose: To identify the effectiveness of nasal hypertonic saline irrigation on reduction of mucociliary transport time (MCTT) and total nasal symptom score (TNSS) in AR patients. Methods: The was conducted from July until December 2016 in Oto Rhino Laryngology - Head and Neck Surgery of Dr. Soetomo Hospital Surabaya. The study was randomized controlled clinical trials on two groups, with the control group in clinical trial design. Paired t and Wilcoxon test was used as the correlation test. Results: There was 42 patients, 21 patients in loratadine group, and 21 patients in loratadine with hypertonic nasal saline group. The average of mucociliary transport time decrease of loratadine with hypertonic nasal saline group was more significant than loratadine group (p=0.001). The mean of decreasing mucociliary transport time in loratadine group was -2.30 (SD=2.77) and loratadine with hypertonic nasal saline group was -6.27 (SD=3.91). The mean of decreasing TNSS in loratadin group was -2.48 (SD=1.72), and loratadin with hypertonic nasal saline group was -4.3 (SD=1.20). Conclusions: The addition of hypertonic nasal saline in loratadine was more effective, compared to monotherapy of loratadine in decreasing mucociliary transport time and TNSS in patient with AR. Keywords: Loratadine, hypertonic nasal saline, mucociliary transport, total nasal symptom score, allergic rhinitis

scholarly journals Therapeutic comparability of Dezrinit and Nazonex® in control of symptoms of allergic rhinitis. The results of a multicenter, open, randomized, comparative study in parallel groups

2016 ◽  
Vol 13 (3) ◽  
pp. 65-74
Author(s):  
N I Ilina ◽  
T G Fedoskova ◽  
N G Astafieva ◽  
L A Gorychkina ◽  
A S Edin ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Symptom Score ◽  
Nasal Spray ◽  
Nasal Symptom ◽  
Ocular Symptom ◽  
Mometasone Furoate ◽  
Total Nasal Symptom Score ◽  
Metered Dose ◽  
Comparison Groups ◽  
Receive Treatment

Background. To study efficacy and safety of Dezrinit (mometasone furoate, metered dose nasal spray, 200 pg/day) in comparison with Nasonex® (mometasone furoate, metered dose nasal spray, 200 pg/day) upon administration for 14 days in adult patients with seasonal allergic rhinitis. Materials and methods. A total of 141 patients were enrolled into the study at 8 study centers in the RF, of which 134 patients were randomized: 67 patients into the experimental group (Dezrinit) and 67 patients into the comparison group (Nasonex®). patients were randomized to receive treatment either with Dezrinit or Nasonex®. Efficacy was assessed based on reflective Total Nasal Symptom Score (rTNSS) and instantaneous Total Nasal Symptom Score (iTNSS); reflective Total Ocular Symptom Score (rTOSS) and instantaneous Total Ocular Symptom Score (iTOSS). Overall proportion of patients who responded to treatment was evaluated according to overall assessment of treatment efficacy both by a patient and by an investigator. AEs were reported for safety assessment. Results. After 14 days of treatment a marked improvement of symptoms was observed in both groups based on all assessed scores. Mean change (SD) in rTNSS from baseline was -11,91 (4,625) scores and -11,64 (4,58) scores in the experimental and comparison groups, respectively (within group differences, p

scholarly journals Efficacy of Mometasone Furoate and Fluticasone Furoate on Persistent Allergic Rhinoconjunctivitis

2013 ◽  
Vol 4 (3) ◽  
pp. ar.2013.4.0065 ◽  
Author(s):  
W. Hamizan Aneeza ◽  
Salina Husain ◽  
Roslenda Abdul Rahman ◽  
Dexter Van Dort ◽  
Asma Abdullah ◽  
...  
Keyword(s):  
Symptom Score ◽  
Nasal Symptom ◽  
Allergic Rhinoconjunctivitis ◽  
Mometasone Furoate ◽  
Fluticasone Furoate ◽  
Ocular Symptoms ◽  
Nasal Symptoms ◽  
Total Nasal Symptom Score ◽  
Significant Difference ◽  
Symptom Scores

Allergic rhinoconjunctivitis denotes both nasal and ocular manifestation of allergy, which may be solely treated with intranasal steroid. This study compares the efficacy of mometasone furoate nasal spray (NS) and fluticasone furoate NS in treatment of allergic rhinoconjunctivitis. The secondary objective is to study the severity of baseline ocular symptoms in allergic rhinoconjunctivitis. Seventy-eight patients with allergic rhinoconjunctivitis were assessed subjectively and objectively using twice-daily symptom scores for nasal (reflective total nasal symptom score [rTNSS] and instantaneous TNSS [iTNSS]) and ocular (reflective total ocular symptom score [rTOSS] and instantaneous TOSS [iTOSS]) symptoms, rhinoconjunctivitis quality-of-life questionnaires (RQOLQs), and acoustic rhinometry. All measurements were taken at baseline and at 4 and 8 weeks of treatment. Sixty-three patients who were randomized into the mometasone furoate group (n = 36) and the fluticasone furoate group (n = 27) completed the study. Seventy-six percent of patients had mild ocular symptoms, 20.5% had moderate symptoms, and only 2.6% had severe symptoms at baseline based on the iTOSS; 65.1% had mild nasal symptoms and 3% had severe nasal symptoms. There was significant reduction in the symptom scores after 1 week (p < 0.05). Both groups had significant improvement in RQOLQ scores after 1 month, which further improved at 2 months (p < 0.05). The nasal dimensions also improved in both groups (p < 0.05) but there was no statistically significant difference between groups. Both mometasone furoate and fluticasone furoate are effective as single-modality treatment of allergic rhinoconjunctivitis. The majority of patients manifest mild ocular symptoms that may be solely treated with intranasal steroids.

A randomized study comparing the efficacy of mometasone furoate and fluticasone furoate on the ocular and nasal symptoms of allergic rhinitis

2017 ◽  
Vol 3 (4) ◽  
pp. 918
Author(s):  
Satvinder Singh Bakshi ◽  
Surianarayanan Gopalakrishnan ◽  
Nirmal Coumare V.
Keyword(s):  
Allergic Rhinitis ◽  
Symptom Score ◽  
Nasal Spray ◽  
Randomized Study ◽  
Nasal Symptom ◽  
Mometasone Furoate ◽  
Fluticasone Furoate ◽  
Ocular Symptoms ◽  
Nasal Symptoms ◽  
Group B

<p class="abstract"><strong>Background:</strong> Ocular symptoms like itching, redness and congestion are common in patients with allergic rhinitis. These symptoms affect the quality of life and increase the burden on the healthcare cost. Intranasal steroids are effective in reducing the nasal and ocular symptoms of allergic rhinitis. We aim to compare the efficacy of mometasone furoate nasal spray and fluticasone furoate nasal spray in reducing the nasal and ocular symptoms of allergic rhinitis.</p><p class="abstract"><strong>Methods:</strong> 90 patients with perennial allergic rhinitis and ocular symptoms were randomly divided into 2 groups. Group A (n=46) received 200 µg of mometasone furoate nasal spray once daily and Group B (n=44) received 110 µg of fluticasone furoate nasal spray daily. The patients were assessed by total ocular symptom score [TOSS] and total nasal symptom score [TNSS] at 2, 6 and 12 weeks interval.  </p><p class="abstract"><strong>Results:</strong> There was a statistically significant reduction in both the groups in respect to the TOSS and TNSS scores. However the improvement in the TOSS score in the fluticasone furoate group was more than the mometasone furoate group by 6 weeks (p=0.0009), which continued till the 12 weeks (p=0.045).</p><p><strong>Conclusions:</strong> Fluticasone furoate is more effective than mometasone furoate in managing the ocular and nasal symptoms of allergic rhinitis. </p>

scholarly journals Clinical Study on Acupuncture Treatment of Perennial Allergic Rhinitis (PAR) Based on Zelen’s Design

2020 ◽  
pp. 1-10
Keyword(s):  
Allergic Rhinitis ◽  
Symptom Score ◽  
Acupuncture Treatment ◽  
Nasal Symptom ◽  
Syndrome Differentiation ◽  
Perennial Allergic Rhinitis ◽  
Total Nasal Symptom Score ◽  
Before And After ◽  
Systemic Symptoms

Abstract Objective: Perennial allergic rhinitis (PAR) is clinically defined as an inflammatory condition of the nose characterised by nasal obstruction, sneezing, itching, or rhinorrhea, occurring for an hour or more on most days throughout the year. The study aimed to evaluate the effectiveness of acupuncture treatment for PAR. Methods: 76 subjects were enrolled with inclusion criteria and randomly divided into the acupuncture group (AG) and drug group (DG) based on Zelen’s design. In AG, Yintang (EX-HN3), LI20 (bilateral), LI11 (left), LI4 (left), ST36 (bilateral) were selected as primary acupoints, and adjunct acupoints were added based on syndrome differentiation. Acupuncture treatment for four weeks was performed once every two days. In DG, Desloratadine Citrate Disodium tablet was administrated orally once every day for four weeks. The variations of total nasal symptom score (TNSS) and overall non-nasal symptom score (TNNSS) were tested within three days before, at Week-4 during, and at Week-4 (follow-up) after the treatment. Results: Thirty-two subjects in the AG and 38 subjects in the DG completed the trial. The differences between TNSS and TNNSS scales in the same groups showed a statistical difference (P<0.05) before, during, and after the treatment. The statistic differences between TNSS and TNNSS in those two groups were not obtained (P＞0.05) before and after the treatment. The differences in those two groups during the follow-up visit were statistically different (P<0.05). Conclusion: Acupuncture could effectively control the nasal and systemic symptoms of PAR, and its effect was more persistent than the administration of Desloratadine Citrate Disodium.

Nasal eosinophilia in nasal smears of patients with persistent and intermittent allergic rhinitis

2018 ◽  
Vol 132 (11) ◽  
pp. 1018-1021 ◽  
Author(s):  
G Berkiten ◽  
İ Aydoğdu ◽  
T L Kumral ◽  
Z Saltürk ◽  
Y Uyar ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Symptom ◽  
Effector Cells ◽  
Total Nasal Symptom Score ◽  
Persistent Allergic Rhinitis ◽  
Symptom Scores ◽  
Intermittent Allergic Rhinitis ◽  
Nasal Cytology ◽  
The Mean ◽  
Non Allergic Rhinitis

AbstractBackgroundEosinophils are the principal effector cells involved in the pathogenesis of allergic rhinitis. Cell numbers increase in non-allergic rhinitis patients with eosinophilia, aspirin hypersensitivity and nasal polyposis, as well as in allergic rhinitis patients. Exfoliative nasal cytology can be used in the differential diagnosis of allergic rhinitis.ObjectiveTo evaluate nasal eosinophilia in nasal smears of patients with mild, persistent and intermittent allergic rhinitis.MethodsThe study comprised 60 patients with allergic rhinitis and 20 healthy volunteers. The patients were divided into intermittent and persistent allergic rhinitis groups. Nasal smear status, eosinophil numbers and Total Nasal Symptom Scores were compared.ResultsNasal smear results were pathological in 40 of 60 allergic rhinitis patients, which was significantly higher than the rate in controls. The mean nasal eosinophilia score was significantly higher in the intermittent allergic rhinitis than in the persistent allergic rhinitis group (p= 0.029). There was a positive correlation between nasal eosinophilia score and Total Nasal Symptom Score (r = 0.652;p< 0.05) in persistent allergic rhinitis and intermittent allergic rhinitis patients.ConclusionThe nasal smear test is inexpensive, objective and simple to perform, and should be part of the diagnostic investigation.

scholarly journals Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Hye Jung Park ◽  
Sae-Hoon Kim ◽  
Yoo Seob Shin ◽  
Chul Hwan Park ◽  
Eun-Suk Cho ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Injection Site ◽  
Symptom Score ◽  
Therapeutic Efficacy ◽  
Controlled Trial ◽  
Life Questionnaire ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Medication Score ◽  
Allergen Extracts

Abstract Background Most previous studies used aluminum hydroxide-absorbed allergen extracts in evaluating the potential therapeutic roles of intralymphatic allergen-specific immunotherapy (ILAIT). In this study, we evaluated the therapeutic efficacy and safety of ILAIT with L-tyrosine-adsorbed allergen extracts of Dermatophagoides farinae, D. pteronyssinus, cat, dog, or mixtures thereof, in patients with allergic rhinitis induced by these allergens. Methods In this randomized, double-blind, placebo-controlled trial, study subjects received three intralymphatic injections of L-tyrosine-adsorbed allergen extracts (active group) or saline (placebo group) at 4-week intervals. Results Although ILAIT reduced daily medication use and skin reactivity to HDM and cat allergens at 4 months after treatment, overall symptom score on a visual analog scale (VAS), sinonasal outcome test-20 (SNOT-20), rhinoconjunctivitis quality of life questionnaire (RQLQ), daily symptom score (dSS), daily medication score (dMS), daily symptom medication score (dSMS), nasal reactivity to HDM allergen, and basophil activity to HDM, cat, and dog allergens at 4 months and 1 year after treatment were similar between the treatment and control groups. Intralymphatic injection was more painful than a venous puncture, and pain at the injection site was the most frequent local adverse event (12.8%); dyspnea and wheezing were the most common systemic adverse events (5.3%). Conclusions ILAIT with L-tyrosine-adsorbed allergen extracts does not exhibit profound therapeutic efficacy in allergic rhinitis and can provoke moderate-to-severe systemic reactions and cause pain at the injection site. Trial registration: clinicaltrials.gov: NCT02665754; date of registration: 28 January 2016

Sign in / Sign up

Export Citation Format

Share Document